OOIR: Observatory of International Research

Papers

(The median citation count of Lancet Gastroenterology & Hepatology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Research in Brief	1241
EASL Congress 2024	431
GORD: pain, PPIs, and preciseness	425
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma	417
Research in Brief	384
Aldafermin in non-alcoholic steatohepatitis: a cautionary tale for trial design	374
Correction to Lancet Gastroenterol Hepatol 2017; 2: 103–11	346
Viral hepatitis: time for action	327
Lucky: Learning to Live Again	327
The changing prevalence of functional constipation: why words matter	288
Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis	248
The role of ERAS in robotic pancreaticoduodenectomy – Authors' reply	242
Treatment withdrawal in Crohn's disease: slowly becoming clearer	239
Immune checkpoint inhibitors in colorectal cancer: dream and reality	230
Trends in alcohol-specific deaths in the UK and industry responses	210
Closing the gender gap in gastroenterology leadership: the need for effective and comprehensive allyship	198
Global multi-stakeholder endorsement of the MAFLD definition	194
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension	185
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium	185
Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic	182
Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial	182
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives	182
Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study	179
A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial	174
International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement	173

AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled	172
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept t	169
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial	168
Research in brief	159
ACG 2024	146
Combined tumour-infiltrating lymphocytes and microsatellite instability status as prognostic markers in colorectal cancer – Authors' reply	138
Rare cause of dysphagia in a young woman	138
Has the time come for a systematic top-down approach in Crohn's disease?	128
Water and sanitation for all	127
The potential of ctDNA in locoregional therapies for colorectal cancer	127
Bringing organ preservation closer for selected patients with rectal cancer	127
Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere	127
Addressing the rise of early-onset colorectal cancer	119
Management of portal vein thrombosis in cirrhosis	114
The present and future of gastroenterology and hepatology: an international SWOT analysis (the GASTROSWOT project)	112
Resmetirom for NASH: balancing promise and prudence	109
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial	107
Correction to Lancet Gastroenterol Hepatol 2022; 7: 627–47	105
Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial	103
Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) programme in Iceland: a population-based study	102
Addressing inequities in access to care among Indigenous peoples with chronic hepatitis C in Alberta, Canada	98
All roads lead to the gut–brain microbiome network	97
Sex and gender in inflammatory bowel disease outcomes and research	97
Long-term VEDOKIDS results: implications for practice and research	97
Local and systemic therapy in liver cancer: the quest for synergy	96
Research in Brief	95
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study	93
Idiopathic gastroparesis consensus misses the patient's voice	93
Availability of point-of-care HBV tests in resource-limited settings	92
Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework	92
Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review	91
Practicalities accessing precision medicine in biliary tract cancer	90
Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED	90
Britta Siegmund: answering the big questions in IBD	87
Management of malignant bowel obstruction – Authors' reply	86
A women-focused matrix mentorship programme in gastroenterology	86
Research in Brief	85
Unifying the approach to tackling inequalities in liver health: learning from working with underserved populations	85
The Year My Life Went Down the Toilet	84
Robotic versus laparoscopic surgery for middle and low rectal cancer	84
Lifting the minority tax in gastroenterology and hepatology	83
Closing the gender gap: building a successful career and leadership in research as a female gastroenterologist	82
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial	81
The relationship between gastrointestinal cancers and the microbiota	78
Hypovolaemic phlebotomy for hepatic resection	77
Diversity in clinical trials: an opportunity and imperative for community engagement	75
Managing inflammatory bowel disease: what to do when the best is unaffordable?	75
Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system	74
Research in Brief	73
Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study	73

Dangerous Medicine	70
CEND-1: a game changer for pancreatic cancer chemotherapy?	69
An unusual complication after a variceal glue injection	69
Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities	69
The growth of faecal microbiota transplantation in the UK: time for a registry?	68
Another arrow in the NASH quiver?	68
Comprehensive screening for superficial oesophageal squamous cell carcinoma and precancerous lesions	68
Shitbag: the story of a diagnosis	67
18th Congress of the European Crohn's and Colitis Organisation	67
Early antiviral therapy in adults with moderate to highly viraemic chronic hepatitis B	67
Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial	66
Urgent action needed to achieve viral hepatitis elimination	66
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial	65
Long-term safety of faecal microbiota transplantation for gastrointestinal diseases in China	64
Machine learning-based automated sponge cytology for screening of oesophageal squamous cell carcinoma and adenocarcinoma of the oesophagogastric junction: a nationwide, multicohort, prospective study	62
Correction to Lancet Gastroenterol Hepatol 2021; 6: 781	60
Bringing dietary therapy for eosinophilic oesophagitis under scientific scrutiny	59
Research in Brief	59
Correction to Lancet Gastroenterol Hepatol 2023; 8: 908–18	58
The world is failing on hunger	58
Immune-checkpoint blockade in surgical management of gastric or gastro-oesophageal junction adenocarcinoma	56
COP27 Climate Change Conference: urgent action needed for Africa and the world	56
Primary intestinal lymphangiectasia	56
Compensation advised for UK victims of contaminated blood scandal	56
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis	56
Induction of microRNA-124 as a novel therapeutic concept in ulcerative colitis	55
Research in brief	55
Clinical management of liver cyst infections: an international, modified Delphi-based clinical decision framework	55
Simplifying HCV treatment: a pathway to elimination and model for delivering health care to vulnerable populations	54
Bowel cancer prevention: are we missing an opportunity?	54
Management of portal vein thrombosis in cirrhosis – Authors' reply	54
Combining systemic and local therapies for hepatocellular carcinoma	54
Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccination	53
The problem of antimicrobial resistance in chronic liver disease	53
Hypovolaemic phlebotomy in patients undergoing hepatic resection at higher risk of blood loss (PRICE-2): a randomised controlled trial	53
The top 10 research priorities for inflammatory bowel disease in children and young adults: results of a James Lind Alliance Priority Setting Partnership	52
Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease	51
Increasing burden of colorectal cancer in China	49
Community pathways for the early detection and risk stratification of chronic liver disease: a narrative systematic review	49
Laparoscopic versus open pancreatoduodenectomy for pancreatic or peri-ampullary tumours	49
The intestinal barrier: a pivotal role in health, inflammation, and cancer	49
Peroral endoscopic myotomy versus pneumatic dilation for achalasia	48
Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study	48
Urgent action needed to eliminate viral hepatitis by 2030	48
Development and validation of the Gender-Equity Model for Liver Allocation (GEMA) to prioritise candidates for liver transplantation: a cohort study	48
PANTS extension study: how best to use anti-TNF drugs in Crohn's disease	48
Effect of COVID-19 on the detection and management of colorectal cancer in England	47
Research in Brief	47
The British Association for the Study of the Liver commitment to equality, diversity, and inclusivity	46
The costs of inadequate toilet coverage in the Philippines	46
DEI in gastroenterology and hepatology	46
Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection	46
Research in Brief	46
Lessons and open questions in borderline resectable pancreatic cancer	45
Standardising early liver transplantation for severe alcohol-related hepatitis	44
Does filgotinib work for Crohn's disease?	44
Gastroenterology training in Africa: an assessment of curriculum and perception	43
HIV pre-exposure prophylaxis as an entry point to the elimination of hepatitis B virus	43
Hepatitis C virus in sub-Saharan Africa: a long road to elimination	43
Cost of colorectal cancer care: sufficient to inform cancer policy?	43
The liver–brain axis in metabolic dysfunction-associated steatotic liver disease	43
Spleen stiffness in portal hypertension algorithms: the next advance	42
Diet or optimised medical therapy for people with irritable bowel syndrome	41
Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD	41
Combination locoregional and systemic therapies in hepatocellular carcinoma	41
Fine-tuning the gut ecosystem: the current landscape and outlook of artificial microbiome therapeutics	41
Early-onset colorectal cancer: Hollyoaks tackles taboos and raises awareness	41
Watch and wait for rectal cancer: towards data-informed surveillance	41
Elimination of hepatitis B requires recognition of catastrophic costs for patients and their families	41
Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial	39
A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised contro	39
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial	39
Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled,	39
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial	38
Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	38
6th World Congress of Paediatric Gastroenterology, Hepatology and Nutrition	37
Research in Brief	37
An open letter to Gavi: hepatitis B birth dose vaccine can't wait	36
A coordinated multipronged attack: integrated care is the future for gastroenterology	36
Research in Brief	36

Polypoid lesions in the stomach and the colon: Cronkhite-Canada syndrome	36
Research in Brief	35
The International Liver Congress 2022	35
Inequities in alcohol-related harm in the Philippines	34
Oncological safety of laparoscopic surgery for low rectal cancer	34
SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy	34
Accelerating point-of-care HCV viral load testing	34
Correction to Lancet Gastroenterol Hepatol 2021; 6: 784–92	34
More is not always better for novel hepatitis B therapies	33
The lottery of primary care for liver disease	33
Infliximab rescue therapy in acute severe ulcerative colitis: more does not equal better	33
Is the attenuated humoral response to COVID-19 vaccination in anti-TNF users relevant?	32
Launch of the International Living Donor Liver Transplantation Outcomes Registry	31
Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study	31
Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by	31
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study	30
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study	29
Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions	29
Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial	29
MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomise	29
Time for a treat all approach for hepatitis B	29
Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial	29
Endoscopic interventions for stricturing Crohn's disease	29
The Liver Meeting 2023	28
Research in Brief	28
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis	28
No accident: the UK infected blood scandal	27
Robotic pancreatoduodenectomy: preparing for the future	27
Stringent criteria for withdrawal of biologics in ulcerative colitis – Authors' reply	26
The case for reducing the use of diagnostic upper and lower gastrointestinal endoscopy	26
Séverine Vermeire: advancing patient-centred research in IBD	25
Challenging stigma around alcohol misuse	25
Vedolizumab in paediatric IBD: a huge step forward but not there yet	25
Ranking treatments in the network meta-analysis should consider the certainty of evidence – Authors' reply	25
Peroral endoscopic myotomy versus pneumatic dilation in treatment-naive patients with achalasia – Authors' reply	25
17th Congress of ECCO	25
Chronic Boom	24
Gastric examination by guided capsule endoscopy: a new era	24
Comparison of trends in early-onset colorectal cancer in North America and Europe	24
Ingestion of high-power magnets: cause for concern	24
Top ten research priorities for alcohol use disorder and alcohol-related liver disease: results of a multistakeholder research priority setting partnership	23
A new chapter in the campaign to eliminate viral hepatitis?	23
Local ablation in pancreatic cancer: some answers and more questions	23
Psychological therapies in inflammatory bowel disease	23
Lessons from a trial of colesevelam for bile acid diarrhoea	22
Oral faecal microbiota transplantation in ulcerative colitis	22
Tackling obesity: drugs are only part of the solution	22
Haematopoietic stem-cell transplantation in Crohn's disease	22
The urgent need to end hepatitis B stigma and discrimination	21
Hypovolaemic phlebotomy to reduce the need for perioperative transfusion: a price worth paying?	21
Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial	21
Implementing metabolic dysfunction-associated steatotic liver disease guidelines in patients with type 2 diabetes	21
Common mental disorders in irritable bowel syndrome: pathophysiology, management, and considerations for future randomised controlled trials	20
Global epidemiology of acute kidney injury in hospitalised patients with decompensated cirrhosis: the International Club of Ascites GLOBAL AKI prospective, multicentre, cohort study	20
A call for advocacy and patient voice to eliminate hepatitis B virus infection	20
Metachronous colorectal cancer risk according to Lynch syndrome pathogenic variant after extensive versus partial colectomy in the Netherlands: a retrospective cohort study	20
Retina and liver fibrosis screening for patients with type 2 diabetes	20
Effect of prophylactic endoscopic clip placement on clinically significant post-endoscopic mucosal resection bleeding in the right colon: a single-centre, randomised controlled trial	19
Terlipressin for hepatorenal syndrome: opportunities and challenges	19
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial	19
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated rand	19
Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial	19
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based th	19
Research in Brief	18
Transmural healing as a therapeutic goal in Crohn's disease: a systematic review	18
A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia	18
Septic arthritis: a presentation of Crohn's disease	17
Prophylactic abdominal drainage after distal pancreatectomy: really unnecessary? – Author's reply	17
Pooling samples for hepatitis C RNA detection	17
Expression of concern—Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre random	17
Research in Brief	17
Minimising the risk of monkeypox virus transmission during faecal microbiota transplantation: recommendations from a European expert panel	17
Single CT colonography versus three rounds of faecal immunochemical test for population-based screening of colorectal cancer (SAVE): a randomised controlled trial	17
Diet or optimised medical therapy for people with irritable bowel syndrome	17
COVID-19: Colorectal cancer endoscopic surveillance in IBD	17
Financing viral hepatitis: catalysing action for impact	17
Are all post-ESWL pancreatitis events clinically significant?	17
Non-coeliac gluten sensitivity: from Salerno to Rome	16
Antibiotic treatment versus appendicectomy for acute appendicitis in adults: an individual patient data meta-analysis	16
Prophylactic abdominal drainage after distal pancreatectomy: really unnecessary?	16
Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions	16
Variceal embolisation plus TIPS for variceal bleeding	16
Africa CDC's viral hepatitis prevention and control programme: a continental initiative to support elimination programmes	16
Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA	16
NAFLD prevalence and severity in overweight and obese populations	16
An important step towards the long-term treatment of eosinophilic oesophagitis	16
No easy way out: blocking lymphocyte egress by the S1P1 receptor 1 modulator tamuzimod in ulcerative colitis	16
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials	16
Clinical outcomes of untreated adults living with chronic hepatitis B in The Gambia: an analysis of data from the prospective PROLIFICA cohort study	15
Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial – Authors' reply	15
A path to global cirrhosis health equity	15
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial	15
SARS-CoV-2 vaccination for patients with inflammatory bowel disease – Authors' reply	15
Liver disease admissions in the UK are increasing, urgently needing local and national solutions	15
Low-dose aspirin and mesalazine for patients with familial adenomatous polyposis	14